Investigational drug · Phase 3
Serplulimab
Also called: HLX10, HLX43
Not approved by FDA. In 25 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
25
25 still active
All registered trials
156
Any phase or sponsor naming "Serplulimab"
First trial start
2020
Apr 17, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Serplulimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer
- Carcinoma, Hepatocellular
- SCLC, Extensive Stage
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Triple Negative Breast Cancer
- NSCLC Stage IV
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Colon Cancer Adenocarcinoma
- Hormone Receptor Positive HER-2 Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Serplulimab" as an intervention, largest first.
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
- A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07318883 · 720 participants (planned) · Start Mar 2026 · Primary completion Jan 2031
Drug: HLX07; HLX07 placebo and 4 more · For: Squamous NSCLC
Sites: Guangzhou, China
- Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaPivotal-lookingRecruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07177443 · 710 participants (planned) · Start Sep 26, 2025 · Primary completion Dec 31, 2035
Drug: Serplulimab; Cisplatin · For: Locally Advanced Nasopharyngeal Carcinoma
Sites: Wuhan, China
Henan Cancer HospitalGovernment (non-federal)
NCT06781281 · 709 participants (planned) · Start Dec 4, 2024 · Primary completion Nov 28, 2026
Drug: Serplulimab; NabPE · For: Breast Cancer Invasive
Sites: Zhengzhou, China
- SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07551479 · 612 participants (planned) · Start May 1, 2026 · Primary completion Dec 31, 2032
Drug: Capecitabine; Oxaliplatin and 1 more · For: Locally Advanced Rectal Cancer (LARC); MSS (Microsatellite Stable)
Sites: Shanghai, China
- A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)Pivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT04547166 · 568 participants (planned) · Start Mar 10, 2021 · Primary completion Sep 24, 2025
Drug: HLX10; HLX04、 · For: Metastatic Colorectal Cancer
Sites: Guangzhou, China; Hangzhou, China; Linyi, China · 5 sites in all
- A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerPivotal-lookingActive, not recruiting
Shanghai Henlius BiotechIndustry
NCT05353257 · 511 participants · Start May 17, 2022 · Primary completion Jun 30, 2026
Drug: HLX10; carboplatin/cisplatin-etoposide and 1 more · For: Limited-Stage Small Cell Lung Cancer
Sites: Arcadia, California; Los Alamitos, California; Los Angeles, California · 129 sites in all
- Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSSPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07877597 · 480 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 31, 2029
Drug: Serplulimab; CapOx(Capecitabine+ Oxaliplatin) · For: Locally Advanced Colon Cancer; pMMR
Sites: Shanghai, China
- A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerPivotal-lookingRecruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07739758 · 442 participants (planned) · Start Aug 18, 2026 · Primary completion Jun 2029
Drug: YL201; Serplulimab and 2 more · For: SCLC, Extensive Stage
Sites: Guangzhou, China; Shenyang, China
- PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal CancerPivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07277842 · 382 participants (planned) · Start Dec 29, 2025 · Primary completion Dec 29, 2028
Drug: Serplulimab; FOLFOXIRI chemotherapy and 1 more · For: Locally Advanced Low Rectal Adenocarcinoma; pMMR (Microsatellite Stable Rectal Cancer)
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study.
Wang T, Ouyang B, Chen L, et al. · Int J Hyperthermia 2026
- Neurological syndrome with CSF anti-Hu positivity during serplulimab therapy in extensive-stage small-cell lung cancer: a case report.
Wang L, Zhao Y, Fan B, et al. · Front Oncol 2026
- Immune checkpoint inhibitor-induced multi-organ immune damage complicated by severe pneumonia: case report.
Zhao T, Chen R, Ma Y, et al. · Front Immunol 2026
- Case Report: Primary squamous cell carcinoma of the pancreas in a 75-year-old woman with a marked response to chemoimmunotherapy and conversion surgery.
Hu X, Shi Y, Yu Q, et al. · Front Med (Lausanne) 2026
- Metachronous bilateral ovarian metastasis with spontaneous rupture following curative resection of stage T4a colon cancer: a case report and literature review.
Zheng Y, Zhang Z · Front Oncol 2026
- Real-World Comparative Survival Outcomes of First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Cohort Study.
Jing Y, Li M, Li S, et al. · J Cancer 2026
Also in development for Non Small Cell Lung Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.